1-甲基-2-乙烯基吡啶三氟甲基磺酸酯 | 339530-78-8

• 物质功能分类: 化学试剂 - 有机试剂 - 甲苯磺酸酯
• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 有机磺酸及其衍生物
• 中文名称: 1-甲基-2-乙烯基吡啶三氟甲基磺酸酯
• 英文名称: 1-Methyl-2-vinylpyridinium triflate
• 英文别名: 2-ethenyl-1-methylpyridin-1-ium;trifluoromethanesulfonate
• CAS: 339530-78-8
• 化学式: C9H10F3NO3S
• 分子量: 269.24
• InChiKey: VJUSJWUMYXKNPL-UHFFFAOYSA-M

物化性质

• 熔点：
  103-110 °C

计算性质

• 辛醇/水分配系数(LogP)：
  1.21
• 重原子数：
  17
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  69.5
• 氢给体数：
  0
• 氢受体数：
  6

安全信息

• 危险品标志：
  Xi
• 安全说明：
  S26,S36
• 危险类别码：
  R36/37/38
• WGK Germany：
  3

反应信息

• 作为反应物：
  描述：

  L-谷胱甘肽 (氧化型) 、 1-甲基-2-乙烯基吡啶三氟甲基磺酸酯 反应 0.5h， 以Cell free supernatant was obtained by centrifugation (50 000 g, 4° C. for 30 minutes)的产率得到谷胱甘肽
  参考文献：
  名称：

  METHOD FOR EVALUATING ASTHMA CONTROL

  摘要：

  使用α-生育酚醌血液水平诊断、监测和评估哮喘患者的哮喘控制方法，以及监测哮喘治疗方案的疗效方法。

  公开号：

  US20070266774A1

文献信息

• Method for decreasing inflammation and oxidative stress in mammals
  申请人：Massimino Stefan Patrick

  公开号：US20080260696A1

  公开（公告）日：2008-10-23

  The present invention is directed to a method for decreasing inflammation and oxidative stress in a mammal comprising; administration to a mammal a composition comprising a glucose anti-metabolite; and wherein said composition comprises amounts of the glucose anti-metabolite sufficient to decrease a level of an oxidized glutathione and/or increase the ration of reduced glutathione to oxidized glutathione in the blood of the mammal subsequent to administration of the glucose anti-metabolite.

  本发明涉及一种降低哺乳动物中炎症和氧化应激的方法，包括向哺乳动物投与含有葡萄糖抗代谢物的组合物，其中所述组合物含有足够量的葡萄糖抗代谢物，以在投与葡萄糖抗代谢物后降低哺乳动物血液中氧化谷胱甘肽水平和/或增加还原谷胱甘肽与氧化谷胱甘肽的比率。
• Methods for preventing or treating insulin resistance
  申请人：Cornell University

  公开号：EP2902036A1

  公开（公告）日：2015-08-05

  The invention provides methods of preventing or treating insulin resistance in a mammalian subject. In particular, the present invention provides a peptide that can be used for normalizing blood glucose levels and/or normalizing insulin response in an insulin resistant mammalian subject.

  本发明提供了预防或治疗哺乳动物胰岛素抵抗的方法。特别是，本发明提供了一种多肽，可用于使胰岛素抵抗的哺乳动物体内的血糖水平正常化和/或使胰岛素反应正常化。
• COMBINATIONS OF PEPTIDE THERAPEUTICS AND METHODS FOR USING SAME
  申请人：Stealth Peptides International, Inc.

  公开号：EP3287172A1

  公开（公告）日：2018-02-28

  Disclosed herein are methods and compositions for the treatment and/or prevention of diseases or conditions comprising administration of GLP-1, and/or naturally or artificially occurring variants or analogues of GLP-1, or pharmaceutically acceptable salts thereof, alone or in combination with one or more active agents (e.g., an aromatic-cationic peptide such as D-Arg-2'6' -Dmt-Lys-Phe-NH2).

  本文公开了用于治疗和/或预防疾病或病症的方法和组合物，包括单独或与一种或多种活性剂（如芳香族阳离子肽，如 D-Arg-2'6'-Dmt-Lys-Phe-NH2）联合施用 GLP-1 和/或 GLP-1 的天然或人工变体或类似物或其药学上可接受的盐。
• Peptide therapeutics and methods for using same
  申请人：Stealth BioTherapeutics Corp

  公开号：US10293020B2

  公开（公告）日：2019-05-21

  Disclosed herein are methods and compositions for the treatment and/or prevention of diseases or conditions comprising administration of an MPP, and/or naturally or artificially occurring variants or analogs of an MPP, or pharmaceutically acceptable salts thereof, alone or in combination with one or more active agents (e.g., an aromatic-cationic peptide such as D-Arg-2′6′-Dmt-Lys-Phe-NH2).

  本文公开了用于治疗和/或预防疾病或病症的方法和组合物，包括单独或与一种或多种活性剂（例如，芳香族阳离子肽，如 D-Arg-2′6′-Dmt-Lys-Phe-NH2）联合施用 MPP 和/或 MPP 的天然或人工变体或类似物或其药学上可接受的盐。
• Therapeutic compositions including frataxin, lactoferrin, and mitochondrial energy generating enzymes, and uses thereof
  申请人：Stealth BioTherapeutics Corp

  公开号：US10576124B2

  公开（公告）日：2020-03-03

  Disclosed herein are methods and compositions for the treatment and/or prevention of diseases or conditions comprising administration of a therapeutic biological molecule, and/or naturally or artificially occurring derivatives, analogues, or pharmaceutically acceptable salts thereof, alone or in combination with one or more active agents (e.g., an aromatic-cationic peptide). The present technology provides compositions related to aromatic-cationic peptides linked to a therapeutic biological molecule and uses of the same. In some embodiments, the aromatic-cationic peptide comprises 2′,6′-dimethyl-Tyr-D-Arg-Phe-Lys-NH2, Phe-D-Arg-Phe-Lys-NH2, or D-Arg-2′,6′-Dmt-Lys-Phe-NH2.

  本文公开了用于治疗和/或预防疾病或病症的方法和组合物，包括施用治疗性生物分子和/或其天然或人工衍生物、类似物或药学上可接受的盐，单独或与一种或多种活性剂（如芳香阳离子肽）结合使用。本技术提供了与治疗性生物分子连接的芳香族阳离子肽相关的组合物及其用途。在一些实施方案中，芳香族阳离子肽包括2′,6′-二甲基-Tyr-D-Arg-Phe-Lys-NH2、Phe-D-Arg-Phe-Lys-NH2或D-Arg-2′,6′-Dmt-Lys-Phe-NH2。